Clinical application of terbinafine in the treatment of superficial mycosis

Abstract

CLC Number:

R978.5

ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of superficial mycosis[J]. Chinese Journal of Mycology, 2020, 15(5): 297-303.

References 59

[1]	Korting HC, Kiencke P, Nelles S, etal. Comparable efficacy and safety of various topical formulations of terbinafine in tineapedis irrespective of the treatment regimen:results of a meta-analysis[J].Am J Clin Dermatol, 2007,8(6):357-364.
[2]	James IG,Loria-Kanza Y, Jones TC.Short-duration topical treatment of tineapedis using terbinafine emulsion gel:results of a dose-ranging clinical trial[J]. J Dermatolog Treat, 2007,18(3):163-168.
[3]	Li RY, Wang AP,Xu JH,et al.Efficacy and safety of 1% terbinafine film-forming solution in Chinese patients with tinea pedis:a randomized, double-blind, placebo-controlled, multicenter, parallel-group study[J].Clin Drug Investig, 2014, 34(3):223-230.
[4]	Brown M, Evans C, Muddle A,et al. Efficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution:a phase IIa, randomised, observer-blind, comparative study[J]. Am J Clin Dermatol, 2013,14(5):413-419.
[5]	Baudraz-Rosselet F, Rakosi T, Wili PB, et al. Treatment of onychomycosis with terbinafine[J]. Br J Dermatol, 1992,126(suppl 39):40-46.
[6]	McClellan KJ, WisemanLR,Markham A. Terbinafine:An update of its use in superficial mycoses[J]. Drugs, 1999,58(1):179-202.
[7]	Auvinen T, Tiihonen R, Soini M,et al.Efficacy of topical resin lacquer, amorolfine and oral terbinafine for treating toenail onychomycosis:a prospective, randomized, controlled, investigator-blinded, parallel-group clinical trial[J]. Br J Dermatol, 2015,173(4):940-948.
[8]	Elewski B, Pollak R, Ashton S,et al. A randomized, placebo-and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis[J]. Br J Dermatol, 2012,166(2):389-398.
[9]	Gupta AK, Lynch LE,Kogan N,et al. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2009, 23(3):256-262.
[10]	Gupta AK, Foley KA, Mays RR,et al.Monotherapy for toenail onychomycosis:a systematic review and network meta-analysis[J]. Br J Dermatol, 2020,182(2):287-299.
[11]	Gupta AK,Stec N, Bamimore MA,et al.The efficacy and safety of pulse vs. continuous therapy for dermatophyte toenail onychomycosis[J]. J Eur Acad Dermatol Venereol, 2020,34(3):580-588.
[12]	Gupta AK,Sibbald RG, AndriessenA,et al.Toenail onychomycosis-A Canadian approach with a new transungual treatment:development of a clinical pathway[J]. J Cutan Med Surg, 2015, 19(5):440-449.
[13]	Ranawaka RR, Nagahawatte A, Gunasekara TA,et al.Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis:A study with 90 patients[J]. J Dermatolog Treat, 2016,27(4):364-372.
[14]	Abu El-Hamd M, Abd Elhameed MI, Shalaby MFM,et al. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis[J]. Dermatol Ther, 2020, 33(3):e13429. doi:10.1111/dth.13429. Online ahead of print.
[15]	Leung AKC, Hon KL, Leong KF,et al.Tinea capitis:an updated review[J]. Recent Pat Inflamm Allergy Drug Discov, 2020,14(1):58-68.
[16]	中国头癣诊疗指南工作组.中国头癣诊断和治疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):4-6
[17]	Drago L, Micali G, Papini M, et al. Management of mycoses in daily practice[J].G Ital Dermatol Venereol, 2017, 152(6):642-650.
[18]	Mercurio MG, E1ewski BE. Tinea capitis treatment[J]. Dennatol Ther, 1997,3:79-83.
[19]	Fuller LC, Barton RC,Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of tinea capitis 2014[J]. Br J Dermatol, 2014,171:454-463.
[20]	Kakourou T, Uksal U, European Society for Pediatric Dermatology.Guidelines for the management of tinea capitis in children[J]. Pediatr Dermatol, 2010,27(3):226-228.
[21]	Devliotou-Panagiotidou D, Koussidou-Eremondi TH. Efficacy and tolerability of 8 weeks' treatment with terbinafine in children with tinea capitis caused by Microsporum Canis:A comparison of Three Doses[J].J Eur Acad Dermatol Venereol,2004,18(2):155-159.
[22]	Gupta AK, Mays RR,Versteeg SG,et al. Tinea capitis in children:a systematic review of management[J]. J Eur Acad Dermatol Venereol, 2018, 32(12):2264-2274.
[23]	Chen X, Jiang X, Yang M,et al.Systemic antifungal therapy for tinea capitis in children[J]. Cochrane Database Syst Rev, 2016,(5):CD004685.
[24]	Kunitake Y, Noguchi H, Hiruma M. Summarization of tinea capitis cases encountered at a clinic in the past 5 years[J].[Article in Japanese] Nihon Ishinkin Gakkai Zasshi, 2009, 50(3):161-166.
[25]	Shwayder T. Terbinafine[J]. J Am Acad Dermatol, 1998,39(1):136.
[26]	van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis:a summary of a Cochrane systematic review[J]. Br J Dermatol, 2015, 172(3):616-641.
[27]	中国体癣和股癣诊疗指南工作组.中国体癣和股癣诊疗指南(2018修订版)[J].中国真菌学杂志,2019,14(1):1-3.
[28]	Gupta AK, Foley KA,Versteeg SG. New antifungal agents and new formulations against dermatophytes[J]. Mycopathologia, 2017, 182(1-2):127-141.
[29]	Bhatia A,Kanish B, Badyal DK, et al. Efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin-A prospective, randomized comparative study[J]. Indian J Pharmacol, 2019,51(2):116-119.
[30]	Shiraki Y, Hiruma M, Inoue A,et al. A short-term treatment of tinea corporis and tinea cruris with oral terbinafine[J]. Nihon Ishinkin Gakkai Zasshi, 2003,44(2):121-125.
[31]	Rich P,Houpt KR, LaMarca A, et al. Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes[J]. Cutis, 2001,68(1 Suppl):15-22.
[32]	de Chauvin MF, Viguié-Vallanet C, Kienzler JL, et al. Novel, single-dose, topical treatment of tinea pedis using terbinafine:results of a dose-finding clinical trial[J]. Mycoses, 2008,51(1):1-6.
[33]	Brown M, Evans C, Muddle A,et al. Efficacy, tolerability and consumer acceptability of terbinafine topical spray versus terbinafine topical solution:a phase IIa, randomised, observer-blind, comparative study[J]. Am J Clin Dermatol, 2013, 14(5):413-419.
[34]	Schäfer-Korting M, Schoellmann C, Korting HC. Fungicidal activity plus reservoir effect allow short treatment courses with terbinafine in tinea pedis[J]. Skin Pharmacol Physiol, 2008,21(4):203-210.
[35]	中国中西医结合学会皮肤性病专业委员会真菌学组,中国医师协会皮肤科分会真菌亚专业委员会,中华医学会皮肤病分会真菌学组.手癣和足癣诊疗指南(2017修订版)[J].中国真菌学杂志,2017,12(6):321-324
[36]	Smith S,Houpt K, Rich P, et al. Short-duration oral terbinafine for the treatment of tinea pedis in HIV-positive patients[J]. Cutis, 2001,68(1 Suppl):30-39.
[37]	Takiuchi I, Morishita N, Hamaguchi T, et al.Treatment outcome and relapse with short-term oral terbinafine (250 mg/day) in tinea pedis[J]. Nihon Ishinkin Gakkai Zasshi, 2005,46(4):285-289.
[38]	Pyatski Y, Flach CR, Mendelsohn R. FT-IR investigation of terbinafine interaction with stratum corneum constituents[J]. Biochim Biophys Acta Biomembr, 2020, 1862(9):183335.
[39]	Kikuchi I,Tanuma H, Morimoto K, et al. Usefulness and pharmacokinetic study of oral terbinafine for hyperkeratotic-type tinea pedis[J]. Mycoses, 2008,51(6):523-531.
[40]	White JE, Perkins PJ, Evans EG. Successful 2-week treatment withterbinafine (Lamisil) for moccasin tinea pedis and tinea manuum[J]. Br J Dermatol,1991,125(3):260-262.
[41]	Tausch I, Decroix J, Gwiezdzinski Z,et al. Short-term itraconazole versus terbinafine in the treatment of tinea pedis or manus[J]. Int J Dermatol, 1998,37(2):140-142.
[42]	Hay RJ, McGregor JM,Wuite J, et al. A comparison of 2 weeks of terbinafine 250 mg/day with 4 weeks of itraconazole100 mg/day in plantar-type tinea pedis[J]. Br J Dermatol,1995,132(4):604-608.
[43]	Shi TW, Zhang JA, Zhang XW, etal.Combination treatment of oral terbinafine with topical terbinafine and 10% urea ointment in hyperkeratotic type tinea pedis[J]. Mycoses, 2014,57(9):560-564.
[44]	Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis:2016 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2016,62(4):e1-50.
[45]	Mendling W, Brasch J, Cornely OA, et al.Guideline:vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis)[J]. Mycoses, 2015,58(Suppl 1):1-15.
[46]	Katoh T. Guidelines for diagnosis and treatment of mucocutaneous candidiasis[J]. Nihon Ishinkin Gakkai Zasshi, 2009,50(4):207-212.[Article in Japanese]
[47]	Balfour JA,Faulds D.Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses[J].Drugs, 1992,43(2):259-284.
[48]	刘耕,于波.盐酸特比萘芬阴道泡腾片治疗念珠菌性阴道炎疗效观察[J]..中国真菌学杂志,2006,1(6):41-42.
[49]	JungEG,Haas PJ,Bräutigam M,et al. Systemic treatment of skin candidosis:A randomized comparison of terbinafine and ketoconazole[J]. Mycoses, 1994,37(9-10):361-365.
[50]	Ferahbas A, Koc AN, Uksal U, et al. Terbinafine versus itraconazole and fluconazole in the treatment of vulvovaginal candidiasis[J]. Am J Ther, 2006,13(4):332-336.
[51]	燕华玲,王爱平,万喆,等.特比萘芬对白念珠菌菌丝相和酵母相敏感性的比较[J].中华皮肤科杂志,2005,38(8):515.
[52]	Yassin MT, Mostafa AA, Al-Askar AA, et al. In vitro antifungal resistance profile of Candida strains isolated from Saudi women suffering from vulvovaginitis[J]. Eur J Med Res, 2020, 25(1):1.
[53]	Shi XY, Yang YP, Zhang Y, et al. Molecular identification and antifungal susceptibility of 186Candida isolates from vulvovaginal candidiasis in southern China[J]. J Med Microbiol, 2015, 64(Pt 4):390-393.
[54]	Faergemann, J, Zehender H, Denouel J, et al. Levels of terbinafine in plasma, stratum-corneum,dermis-epidermis(without stratumcorneum), sebum, hair and nails during and after 250 mg terbinafine orally once per day for 4 weeks[J]. Acta Dermato-Venereol, 1993, 73:305-309.
[55]	秦晓华,王明贵,Kanafani ZA,等.抗真菌药物的耐药机制及其临床意义[J]. 中国感染与化疗杂志,2010,10(4):320.
[56]	Hsieh A,Quenan S, Riat A, et al.A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis[J]. J Mycol Med, 2019,29(4):352-355.
[57]	Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine:results of a postmarketing surveillance study in 25,884 patients[J]. Arch Dermatol, 1997,133(10):1213-1219.
[58]	Stolmeier DA, Stratman HB, McIntee TJ,et al. Utility of laboratory test result monitoring in patients taking oral terbinafine or griseofulvin for dermatophyte infections[J]. JAMA Dermatol, 2018, 154(12):1409-1416.
[59]	Wang Y, Lipner SR. Retrospective analysis of adverse events with systemic onychomycosis medications reported to the United States Food and Drug Administration[J].J Dermatolog Treat,2020:1-5.[Epub ahead of print]

Clinical application of terbinafine in the treatment of superficial mycosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 59

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHU Hong-mei, WEN Hai. Clinical application of terbinafine in the treatment of subcutaneous and deep mycosis [J]. Chinese Journal of Mycology, 2020, 15(6): 374-377.
[2]	LIU Jie, LIU Xiao-yun, YU Bo, HU Xiao-ping. Analysis on pathogenic characteristics of dermatophyte infection and in vitro drug susceptibility of 85 strains of dermatophyte [J]. Chinese Journal of Mycology, 2019, 14(6): 351-356.
[3]	JIANG Wei-wei, HU Dong-ying, HOU Qing, DU Ming-wei, LI Hang, DENG Yu-chen, LI Shuai, CAO Yun, ZHENG Fang-wei, LING Li-yan, YU Xiao-tian, FANG Wen-jie, ZHAO Jin, PAN Wei-hua, LIAO Wan-qing. Analysis of 1031 cases of dermatophytosis and the pathogenic dermatophytes [J]. Chinese Journal of Mycology, 2019, 14(2): 99-103.
[4]	ShaoXia, QiaoJian-jun. Tinea incognito on the neck with long-term misdiagnosis [J]. Chinese Journal of Mycology, 2019, 14(1): 45-46.
[5]	HU Xiao-ping, GAO Lu-juan, YOU Li-ping, LI Ruo-yu. A case of Majocchi's granuloma (MG) and onychomycosis caused by Trichophyton rubrum in a renal transplant recipient [J]. Chinese Journal of Mycology, 2018, 13(4): 241-243.
[6]	WU Qian-qian, SHI Lei, ZHANG Hai-yan, ZHANG Ling-lin, GAO Zhi-qin, YANG Hong, YANG Lian-juan, WANG Xiu-li. In vitro study of the 5-aminolevulinic acid photodynamic therapy for Trichophyton tonsurans strain isolated from granuloma [J]. Chinese Journal of Mycology, 2018, 13(3): 139-143.
[7]	WU Yan, KONG Jian, YUAN Hai-long, ZHANG Fu-cheng. Histopathological observation of terbinafine hydrochloride gel against dermatophytes infection [J]. Chinese Journal of Mycology, 2017, 12(5): 283-287.
[8]	LEI Wen-zhi, DU Lin, WEI Feng-lian, LIAO Wan-qing, WEN Hai. A randomized,double-blind,controlled study with luliconazle cream (1%) versus terbinafine cream (1%) in patients with tinea cruris [J]. Chinese Journal of Mycology, 2017, 12(1): 38-41.
[9]	ZHU Min, SU Hui-lin, LI Li, CHENG Ben-lin, ZHU Jun-hao, ZHANG Qiang-qiang. Evaluation of efficacy and safety of 1% luliconazole cream in the treatment of tinea corporis and tinea cruris [J]. Chinese Journal of Mycology, 2017, 12(1): 42-44.
[10]	GAO Fei, CAO Ping. Study of 1% luliconazole cream and 1% terbinafine cream in the treatment of tinea pedis:a randomized controlled,single-blind trial [J]. Chinese Journal of Mycology, 2016, 11(5): 304-306.
[11]	BU Xiao-lin, FAN Juan, HU Xiao-li, JIANG Jian-hua, QU Zi-wei, GU Jun. Antifungal susceptibilities of 36 isolates from tinea pedis evaluated with CLSI M38-A2 and M27-A3 schemes [J]. Chinese Journal of Mycology, 2016, 11(3): 169-173.
[12]	ZHU Jun-hao, HAN De-min, ZHAO Ying, LI Li, ZHANG Qiang-qiang. Etiologic analysis of 9 566 cases of superficial mycosis in Shanghai region [J]. Chinese Journal of Mycology, 2016, 11(3): 178-180.
[13]	FAN Jian-feng, Lin Bi-wei, Li Heng-jin. The antifungal susceptibility test in vitro of luliconazole ethosomes [J]. Chinese Journal of Mycology, 2016, 11(1): 13-15.
[14]	WANG You-wei, LUO Cai-hui, LI Hong-xia, YANG Yang, ZHAO Wei, LIU Chun-jiang. An analysis of isolates of pathogenic fungi from 47766 suspected skin mycosis outpatients [J]. Chinese Journal of Mycology, 2016, 11(1): 37-40.
[15]	ZHANG Jing, CAI Wen-ying, XIAO Xing, MA Jian-chi, XI Li-yan. Evaluation of efficacy and safety of 1% luliconazole cream in the treatment of tinea pedis [J]. Chinese Journal of Mycology, 2016, 11(1): 48-50.